Clinical Trials Detail

Targeted Therapy Directed by Genetic Testing in Patients With Solid Tumors, Lymphomas, or MM

Molecular Analysis for Therapy Choice (MATCH)

Objective
CategoryInformation
Study #: EAY131 - MATCH
Anatomic Site: Any
Histology:
  • Advanced Malignant Neoplasm
  • Lymphoma
  • Recurrent Plasma Cell Myeloma
  • Recurrent Solid Neoplasm
  • Refractory Malignant Neoplasm
  • Refractory Plasma Cell Myeloma
Mutation:
  • EGFR
  • HER2
  • EGFR T790M
  • BRAF V600E/R/K/D
  • PIK3CA
  • PTEN
  • PTEN deletion
  • PTEN loss
  • HER2 amplification
  • BRAF fusion
  • BRAF non-V600
  • NF 1
  • GNAQ
  • GNA11
  • SMO
  • PTCH1
  • NF2 inactivating
  • cKIT exon 9
  • cKIT exon 11
  • cKIT exon 13
  • cKIT exon 14
  • FGFR pathway aberrations
  • DDR2 S768R
  • I638F
  • L239R
  • Akt
  • NRAS in codon 12
  • NRAS in codon 13
  • NRAS in codon 61
  • CCND1, 2, or 3 amplification with Rb by IHC
  • Loss of MLH1 or MSH2 by IHC
Stage: Advanced
Treatment Phase: Patient must have histologically documented solid tumors or confirmed diagnosis of lymphoma or multiple myeloma requiring therapy. Patients must have progressed following at least one line of standard systemic therapy; no standard treatment exists for their disease. Must have measurable disease.
Location:
Study Link: https://clinicaltrials.gov/ct2/show/NCT02465060?term=EAY131&rank=1

Clinical Trial Categories

  • Any